186393-22-6

Basic information

• Product Name: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate
• Synonyms: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;rel-(3R,4S)-tert-Butyl 3,4-dihydroxypyrrolidine-1-carboxylate;cis-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate;tert-Butyl (3R,4S)-3,4-dihydroxypyrrolidine-1-carboxylate;tert-butyl-cis-3,4-dihydroxypyrrolidine-1-carboxylate;1-Pyrrolidinecarboxylic acid, 3,4-dihydroxy-, 1,1-dimethylethyl ester, (3R,4S)-rel-
• CAS NO: 186393-22-6
• Molecular Formula: C9H17NO4
• Molecular Weight: 203.23558
• Mol File: 186393-22-6.mol
• Article Data: 38

Chemical Properties

• Boiling Point: 300.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.262±0.06 g/cm3(Predicted)
• PKA: 13.91±0.40(Predicted)
• CAS DataBase Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)
• EPA Substance Registry System: (3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate(186393-22-6)

Safety Data

• Hazardous Substances Data: 186393-22-6(Hazardous Substances Data)

Usage

Uses

(3R,4S)-tert-butyl 3,4-dihydroxypyrrolidine-1-carboxylate is a heterocyclic derivative and can be used as a pharmaceutical intermediate.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 114214-49-2 rac-tert-butyl (1R,5S)-6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate 
• 73286-70-1 N-(tert-butoxycarbonyl)-3-pyrroline 
• 86953-79-9 tert-butyl pyrrolidine-1-carboxylate 
• 114214-49-2 1-tert-butoxycarbonyl-3,4-epoxypyrrolidine 
• 4248-19-5 tert-butyl carbazate 
• 151259-38-0 tert-butyl diallylcarbamate 
• 60138-51-4 tert-butyl 2,5-dihydropyrrole 
• 163439-82-5 (3R,4R)-1-benzyl-3,4-pyrrolidinediol 
• 186393-31-7 (3R,4R)-pyrrolidine-3,4-diol 
• 1428671-12-8 (3S,4S)-1-(tert-butoxycarbonyl)-3,4-pyrrolidinediyl diacetate 
• 762-75-4 tert-butyl formate 
• 90481-32-6 (3S,4S)-pyrrolidine-3,4-diol 
• 90365-74-5 (3S,4S)-(+)-1-benzyl-3,4-pyrrolidinediol 

Downstream Products

• 945217-60-7 tert-butyl (3R,4S)-3,4-diaminopyrrolidine-1-carboxylate 
• 694439-03-7 tert-butyl (4aS,7aS)-hexahydro-6H-[1,4]dioxino[2,3-c]pyrrolidine-6-carboxylate 
• 694439-03-7 tert-butyl (4aR,7aS)-hexahydro-2H-[1,4]dioxino[2,3-c]pyrrole-6-carboxylate 
• 148214-86-2 rac-tert-butyl (3R,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 372482-11-6 tert-butyl (3S,4S)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 148214-86-2 tert-butyl (3R,4R)-3-hydroxy-4-methoxypyrrolidine-1-carboxylate 
• 276862-76-1 (3S,4S)-pyrrolidine-3,4-diol hydrochloride 
• 503552-68-9 (3R,4R)-1-N-tert-butyloxycarbonyl-3,4-diaminopyrrolidine 

Relevant articles and documents

Discovery of 1-pyrimidinyl-2-aryl-4,6-dihydropyrrolo [3,4-d]imidazole-5(1H)-carboxamide as a novel JNK inhibitor

We designed and synthesized 1-pyrimidinyl-2-aryl-4, 6-dihydropyrrolo [3,4-d] imidazole-5(1H)-carboxamide derivatives as selective inhibitors of c-Jun-N-terminal Kinase 3 (JNK3), a target for the treatment of neurodegenerative diseases. Based on the compounds found in previous studies, a novel scaffold was designed to improve pharmacokinetic characters and activity, and compound 18a, (R)-1-(2-((1-(cyclopropanecarbonyl)pyrrolidin-3-yl)amino)pyrimidin-4-yl)-2-(3,4-dichlorophenyl)-4,6-dihydro pyrrolo [3,4-d]imidazole-5(1H)-carboxamide, showed the highest IC50 value of 2.69 nM. Kinase profiling results also showed high selectivity for JNK3 among 38 kinases, having mild activity against JNK2, RIPK3, and GSK3β, which also known to involve in neuronal apoptosis.

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.